Dublin, Ireland

Shona Harmon

This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignee: Solvotrin Therapeutics Limited. Active years: 2017.


% Patents Active = 100.0

 

Average Co-Inventor Count = 6.0

ph-index = 1


Company Filing History:


Years Active: 2017

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Shona Harmon: Innovator in Pharmaceutical Compounds

Introduction

Shona Harmon is a notable inventor based in Dublin, Ireland. She has made significant contributions to the field of pharmaceuticals, particularly with her innovative work on compounds that exhibit super-aspirin effects. Her research and inventions have the potential to impact the medical community positively.

Latest Patents

Shona Harmon holds a patent for her invention titled "Compounds with super-aspirin effects." This patent describes a compound characterized by a specific structural formula, which includes various aryl esters and alkylaryl esters. The compounds are designed to release nitric oxide and other functional groups, aiming to produce enhanced therapeutic effects similar to aspirin.

Career Highlights

Throughout her career, Shona has demonstrated a commitment to advancing pharmaceutical science. Her work at Solvotrin Therapeutics Limited has positioned her as a key player in the development of innovative therapeutic compounds. She has successfully navigated the complexities of patent applications, securing her intellectual property rights.

Collaborations

Shona has collaborated with esteemed colleagues, including John Francis Gilmer and Mark Ledwidge. These partnerships have fostered a collaborative environment that encourages innovation and the sharing of ideas.

Conclusion

Shona Harmon is a pioneering inventor whose work in pharmaceutical compounds showcases her dedication to improving health outcomes. Her contributions to the field are invaluable, and her innovative spirit continues to inspire others in the industry.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…